Accession Number : AD1064689


Title :   Cannabidivarin (CBDV) Versus Placebo in Children with Autism Spectrum Disorder (ASD)


Descriptive Note : Technical Report,01 Aug 2017,31 Jul 2018


Corporate Author : Albert Eintsein College of Medicine, Inc. Bronx United States


Personal Author(s) : Hollander, Eric


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1064689.pdf


Report Date : 01 Aug 2018


Pagination or Media Count : 42


Abstract : The CDC currently estimates 1 in 59 children have Autism Spectrum Disorder (ASD). Children with ASD have problems with social communication, irritability, repetitive behaviors, impulsivity, temper tantrums, and a high caregiver burden. The only medications approved by the FDA for symptoms of ASD are aripiprazole and risperidone. Both of these are used to reduce irritability but have short-term and long-term side effects.


Descriptors :   autism , neurodevelopmental disorders , biomedical research


Subject Categories : Medicine and Medical Research
      Psychology


Distribution Statement : APPROVED FOR PUBLIC RELEASE